Amgen’s R&D Group Focuses On Efficiency As Drug Cost Concerns Continue

Amgen Inc. has been working for years to improve the efficiency of its research and development group, but executive vice president of R&D David Reese said that when he moved into his role 18 months ago he looked at additional ways to streamline the organization so that it works within an industry business model that’s changing based on increasing concerns about the costs of new drugs.

“What I really did was take a basic approach and say, 'OK, what are our assumptions about the world over the next 10-15 years?’” Reese said in an interview during the recent J.P. Morgan Healthcare Conference in San Francisco